Rezera Inc., a clinical-stage biotechnology company, filed a Form S-1 registration statement with the SEC on October 21, 2026, to register shares of its common stock in an initial public offering (IPO). The company stated that prior to this offering, there has been no public market for its common stock. It plans to list the shares on the Nasdaq Market under the symbol "RZRA." The filing includes typical IPO details such as underwriting arrangements and the company's status as an emerging growth company and smaller reporting company.
Why it matters
Investors may want to monitor this IPO as it introduces a new public biotech company focused on NLRP3 inhibitors for treating inflammation-related diseases. The offering could affect market dynamics within the biotech sector and provide investment opportunities once the registration becomes effective.
Explore our permanent IPO company profile for the developing timeline.
This report is based on the official SEC S-1 filing dated 20261021. Offering terms may change; review the primary filing before making a decision.